Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 + oxaliplatin + S-1 as neoadjuvant therapy for locally advanced gastric and gastroesophageal junction adenocarcinoma
ChiCTR2500111114Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhongshan Hospital (Xiamen), Fudan University. Primary endpoints: Pathologic complete remission and Overall survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500111114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111114.